icon-    folder.gif   Conference Reports for NATAP  
 
  18th CROI
Conference on Retroviruses
and Opportunistic Infections
Boston, MA
February 27 - March 2, 2011
Back grey_arrow_rt.gif
 
 
 
Interim Analysis of Phase 2a Study of Telaprevir + Peginterferon/Ribavirin in HCV/HIV Coinfected Patients
 
 
  Reported by Jules Levin
CROI 2011 March 2 Boston
 
CROI: Clinical Pharmacology of Boceprevir: Metabolism, Excretion, and Drug-Drug Interactions - (03/2/11)
 
CROI: Pharmacokinetic Interactions Between Antiretroviral Agents and the Investigational HCV Protease Inhibitor Telaprevir in Healthy Volunteers - (03/2/11)
 
from Jules: This is a small study where patients received efavirenz or Reyataz/r or no AT along with triple HCV therapy including telaprevir, an HCV protease inhibitor. Hit the link above and you can see the telaprevir drug-drug interaction studies with ARTs and you'll see the interactions are too great with the other ARTs except for efavirenz and Reyataz/r so patients at this time can only take Reyataz/r or efavirenz along with telaprevir & peg/rbv. Soon a interaction study with raltegravir will be conducted but an interaction is not expected.

apasl1.gif

apasl2.gif

apasl3.gif

apasl4.gif

apasl5.gif

apasl6.gif

apasl7.gif

apasl8.gif

apasl9.gif